To assess the risks of pharmaceuticals released in the environment, focusing on cytostatic drugs.
1) To develop new analytical methods for assessment of the occurrence and fate of cytostatic pharmaceuticals, their metabolites and transformation products in water treatment systems and in the environment, 2) To explore potential delayed and irreversible effects of cytostatic pharmaceuticals at environmentally relevant concentrations in aquatic experimental models, and compare the data to those obtained in human experimental models, 3) To explore combined effects of mixtures of cytostatic pharmaceuticals, their excreted metabolites and transformation products formed in the environment and/or wastewater treatment, 4) To develop, based on the obtained results, guidance on how to improve the environmental and human risk assessment of cytostatics released into the environment.
- Fate and Effects of Cytostatic Pharmaceuticals in the Environment and Identification of Biomarkers for an Improved Risk Assessment on Environmental Exposure
- Fate and Effects of Cytostatic Pharmaceuticals in the Environment and Identification of Biomarkers for an Improved Risk Assessment on Environmental Exposure
- Occurrence, fate and determination of cytostatic pharmaceuticals in the environment
- Final Report Summary – CYTOTHREAT (Fate and effects of cytostatic pharmaceuticals in the environment and the identification of biomarkers for and improved risk assessment on environmental exposure)
- γ-H2AX as a biomarker for DNA double-strand breaks in ecotoxicology
- Estrogenic activity and cytotoxicity of six anticancer drugs detected in water systems
- Toxicities of four anti-neoplastic drugs and their binary mixtures tested on the green alga Pseudokirchneriella subcapitata and the cyanobacterium Synechococcus leopoliensis
- Study of the stability of 26 cytostatic drugs and metabolites in wastewater under different conditions
- Shear-induced hydrodynamic cavitation as a tool for pharmaceutical micropollutants removal from urban wastewater
- Fluorouracil in the environment: Analysis, occurrence, degradation and transformation
- Removal of pharmaceuticals from wastewater by biological processes, hydrodynamic cavitation and UV treatment
HCWH Europe gratefully acknowledges the financial support of the European Commission (EC)’s LIFE+ programme, the Federal Ministry for the Environment, Nature Conservation, and Nuclear Safety (BMU) Germany, and the German Environment Agency (UBA). HCWH Europe is solely responsible for the content of this project and related materials. The views expressed do not reflect the official views of the EC, BMU, or UBA.




